{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:25:06Z","timestamp":1793755506694,"version":"4.6.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006593","name":"CANVAS Scientific Advisory Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health and Medical Research Council of Australia","award":["14\/029\/001"],"award-info":[{"award-number":["14\/029\/001"]}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["14\/743"],"award-info":[{"award-number":["14\/743"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.vaccine.2018.10.001","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T10:42:19Z","timestamp":1539686539000},"page":"6968-6978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["An economic case for a vaccine to prevent group A streptococcus skin infections"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1321-9605","authenticated-orcid":false,"given":"Jeffrey W.","family":"Cannon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9421-1631","authenticated-orcid":false,"given":"Susan","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3121-5405","authenticated-orcid":false,"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Geelhoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Carapetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2018.10.001_b0005","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1542\/peds.2006-3368","article-title":"Burden of acute sore throat and group A streptococcal pharyngitis in school-aged children and their families in Australia","volume":"120","author":"Danchin","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.10.001_b0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1186\/s12879-014-0727-5","article-title":"The microbiology of impetigo in indigenous children: associations between streptococcus pyogenes, staphylococcus aureus, scabies, and nasal carriage","volume":"14","author":"Bowen","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.001_b0015","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1371\/journal.pntd.0000467","article-title":"High Burden of Impetigo and Scabies in a Tropical Country","volume":"3","author":"Steer","year":"2009","journal-title":"PLoS Neglected Tropical Diseases."},{"issue":"8","key":"10.1016\/j.vaccine.2018.10.001_b0020","doi-asserted-by":"crossref","first-page":"e0136789","DOI":"10.1371\/journal.pone.0136789","article-title":"The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma","volume":"10","author":"Bowen","year":"2015","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.vaccine.2018.10.001_b0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.5694\/j.1326-5377.2007.tb01054.x","article-title":"The epidemiology of invasive group A streptococcal disease in Victoria, Australia","volume":"186","author":"O'Grady","year":"2007","journal-title":"Med J Aust"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.001_b0030","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/cid\/ciw248","article-title":"Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005\u20132012","volume":"63","author":"Nelson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2018.10.001_b0035","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJMoa1603693","article-title":"Global, regional, and national burden of rheumatic heart disease, 1990\u20132015","volume":"377","author":"Watkins","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2018.10.001_b0040","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.001_b0045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/INF.0b013e318281da11","article-title":"Progress toward a global group a streptococcal vaccine","volume":"32","author":"Steer","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"26","key":"10.1016\/j.vaccine.2018.10.001_b0050","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1016\/j.vaccine.2016.03.073","article-title":"Status of research and development of vaccines for Streptococcus pyogenes","volume":"34","author":"Steer","year":"2016","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2018.10.001_b0055","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1016\/j.vaccine.2011.09.005","article-title":"New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci","volume":"29","author":"Dale","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.001_b0060","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1128\/IAI.70.4.2171-2177.2002","article-title":"Immunogenicity of a 26-valent group A streptococcal vaccine","volume":"70","author":"Hu","year":"2002","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2018.10.001_b0065","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1086\/444458","article-title":"Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers","volume":"41","author":"McNeil","year":"2005","journal-title":"Clin Inf Dis: Off Publ Inf Dis Soc Am"},{"issue":"10","key":"10.1016\/j.vaccine.2018.10.001_b0070","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1473-3099(09)70178-1","article-title":"Global emm type distribution of group A streptococci: systematic review and implications for vaccine development","volume":"9","author":"Steer","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2018.10.001_b0075","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/374800","article-title":"Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8-and diphtheria toxoid-specific antibodies to protection","volume":"187","author":"Batzloff","year":"2003","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.001_b0080","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymeth.2009.03.024","article-title":"A vaccine against S. pyogenes: design and experimental immune response","volume":"49","author":"Guilherme","year":"2009","journal-title":"Methods"},{"issue":"26","key":"10.1016\/j.vaccine.2018.10.001_b0085","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1016\/j.vaccine.2016.02.078","article-title":"Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7\u20139th Sep 2015","volume":"34","author":"Giersing","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.001_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.10.090","article-title":"Report from the World Health Organization\u2019s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8\u201310th June 2016","author":"Giersing","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.001_b0095","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-0484","article-title":"Burden and economic cost of group A streptococcal pharyngitis","volume":"121","author":"Pfoh","year":"2008","journal-title":"Pediatrics"},{"issue":"33","key":"10.1016\/j.vaccine.2018.10.001_b0100","doi-asserted-by":"crossref","first-page":"20556","DOI":"10.2807\/1560-7917.ES2013.18.33.20556","article-title":"Increased incidence of invasive group A streptococcal disease in Ireland, 2012 to 2013","volume":"18","author":"Meehan","year":"2013","journal-title":"Euro Surveill"},{"issue":"14","key":"10.1016\/j.vaccine.2018.10.001_b0105","doi-asserted-by":"crossref","first-page":"20443","DOI":"10.2807\/1560-7917.ES2013.18.14.20443","article-title":"Increased incidence of invasive group A streptococcal infections in Sweden, January 2012-February 2013","volume":"18","author":"Darenberg","year":"2013","journal-title":"Euro Surveill"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.001_b0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jinf.2014.09.001","article-title":"Increasing incidence of invasive group A streptococcus disease in New Zealand, 2002\u20132012: a national population-based study","volume":"70","author":"Williamson","year":"2015","journal-title":"J Infec"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.001_b0115","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S1473-3099(17)30693-X","article-title":"Resurgence of scarlet fever in England, 2014\u201316: a population-based surveillance study","volume":"18","author":"Lamagni","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.001_b0120","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JCM.00422-08","article-title":"Epidemiology of severe streptococcus pyogenes disease in Europe","volume":"46","author":"Lamagni","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.10.001_b0125","series-title":"Host-pathogen interactions in streptococcal diseases","first-page":"1","article-title":"Group A streptococcal diseases and their global burden","author":"Ralph","year":"2013"},{"issue":"9","key":"10.1016\/j.vaccine.2018.10.001_b0130","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2165\/11634180-000000000-00000","article-title":"Invasive group A streptococcal disease","volume":"72","author":"Steer","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2018.10.001_b0135","series-title":"The health and welfare of Australia\u2019s Aboriginal and Torres Strait Islander peoples 2015. Cat. no. IHW 147","author":"Australian Institute of Health and Welfare","year":"2015"},{"key":"10.1016\/j.vaccine.2018.10.001_b0140","series-title":"Housing circumstances of indigenous households: tenure and overcrowding. Cat. no. IHW 132","author":"Australian Intitute of Health and Welfare","year":"2014"},{"issue":"9995","key":"10.1016\/j.vaccine.2018.10.001_b0145","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Vos","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.10.001_b0150","unstructured":"PBAC. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee version 4.5; 2015 [June, 2016]. Available from: https:\/\/pbac.pbs.gov.au\/information\/printable-version-of-guidelines.html."},{"key":"10.1016\/j.vaccine.2018.10.001_b0155","unstructured":"Vos T, Carter R, Barendregt J, Mihalopoulos C, Veerman L, Magnus A, et al. Assessing cost-effectiveness in prevention: ACE\u2013prevention September 2010 final report: University of Queensland; 2010."},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.001_b0160","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s12879-016-1891-6","article-title":"Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development","volume":"16","author":"Williamson","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2018.10.001_b0165","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.vaccine.2013.01.019","article-title":"Potential coverage of a multivalent M protein-based group A streptococcal vaccine","volume":"31","author":"Dale","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.001_b0170","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/INF.0b013e3182a5c32a","article-title":"Group A streptococcal emm type prevalence among symptomatic children in cape town and potential vaccine coverage","volume":"33","author":"Engel","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.vaccine.2018.10.001_b0175","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1017\/S0950268815002927","article-title":"Group A streptococcal strains isolated in Lao People's Democratic Republic from 2004 to 2013","volume":"144","author":"Rattanavong","year":"2016","journal-title":"Epidemiol Infect"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.001_b0180","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.pathol.2017.09.001","article-title":"M protein gene (emm type) analysis of group A streptococcus isolates recovered during an acute glomerulonephritis outbreak in northern Western Australia","volume":"49","author":"Speers","year":"2017","journal-title":"Pathology."},{"key":"10.1016\/j.vaccine.2018.10.001_b0185","series-title":"Estimates and projections, Aboriginal and Torres Strait Islander Australians, 2001 to 2026, cat. no. 3238.0","author":"Australian Bureau of Statistics","year":"2014"},{"key":"10.1016\/j.vaccine.2018.10.001_b0190","series-title":"Australian demographic statistics, Dec 2016 , cat. no. 3101.0","author":"Australian Bureau of Statistics","year":"2017"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.001_b0195","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/hec.1612","article-title":"Discounting and decision making in the economic evaluation of health-care technologies","volume":"20","author":"Claxton","year":"2011","journal-title":"Health Econ"},{"key":"10.1016\/j.vaccine.2018.10.001_b0200","unstructured":"PHARMAC. Guidelines for funding applications to PHARMAC 2015 [June, 2016]. Available from: https:\/\/www.pharmac.govt.nz\/assets\/guidelines-for-funding-applications-2015-08.pdf."},{"key":"10.1016\/j.vaccine.2018.10.001_b0205","series-title":"Global burden of disease study 2016 (GBD 2016) incidence, prevalence, and years lived with disability 1990\u20132016","author":"Global Burden of Disease Collaborative Network","year":"2017"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.001_b0210","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/INF.0000000000001558","article-title":"Acute rheumatic fever after group A streptococcus pyoderma and group G streptococcus pharyngitis","volume":"36","author":"O'Sullivan","year":"2017","journal-title":"Pediat Inf Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.001_b0215","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/506938","article-title":"Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic","volume":"43","author":"McDonald","year":"2006","journal-title":"Clin Inf Dis: Off Publ Inf Dis Soc Am"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.001_b0220","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/tmi.12405","article-title":"Changes in the clinical and epidemiological features of group A streptococcal bacteraemia in Australia's Northern Territory","volume":"20","author":"Gear","year":"2015","journal-title":"Trop Med Int Health: TM & IH"},{"issue":"5","key":"10.1016\/j.vaccine.2018.10.001_b0225","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1161\/CIRCULATIONAHA.113.001477","article-title":"Acute rheumatic fever and rheumatic heart disease: incidence and progression in the Northern Territory of Australia, 1997 to 2010","volume":"128","author":"Lawrence","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.001_b0230","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2018.10.001_b0235","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1093\/cid\/civ655","article-title":"Inability of polymerase chain reaction, pyrosequencing, and culture of infected and uninfected site skin biopsy specimens to identify the cause of cellulitis","volume":"61","author":"Crisp","year":"2015","journal-title":"Clin Inf Dis: Off Publ Inf Dis Soc Am"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.001_b0240","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S0950268809990483","article-title":"Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review","volume":"138","author":"Chira","year":"2010","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2018.10.001_b0245","series-title":"Infectious diseases","author":"Cohen","year":"2016"},{"key":"10.1016\/j.vaccine.2018.10.001_b0250","series-title":"Microbiology in clinical practice","author":"Shanson","year":"2014"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.001_b0255","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1017\/S0950268812000763","article-title":"Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England","volume":"141","author":"Chapman","year":"2013","journal-title":"Epidemiol Infect"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.001_b0260","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/infdis\/jiu213","article-title":"Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England","volume":"210","author":"Moore","year":"2014","journal-title":"J Inf Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.001_b0265","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.vaccine.2015.11.053","article-title":"Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: uncertain herd impact on pneumonia critical","volume":"34","author":"Newall","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.001_b0270","doi-asserted-by":"crossref","first-page":"A29","DOI":"10.1016\/j.vaccine.2016.12.001","article-title":"Moving beyond traditional valuation of vaccination: needs and opportunities","volume":"35","author":"Bloom","year":"2017","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2018.10.001_b0275","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1001\/jama.2013.281452","article-title":"Excessive antibiotic prescribing for sore throat and acute bronchitis remains common","volume":"310","author":"Kuehn","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.10.001_b0280","series-title":"Streptococcal infections: clinical aspects, microbiology, and molecular pathogenesis","author":"Stevens","year":"2000"},{"key":"10.1016\/j.vaccine.2018.10.001_b0285","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000023.pub2","article-title":"Antibiotics for sore throat","volume":"2","author":"Del Mar","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.vaccine.2018.10.001_b0290","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00431-014-2395-2","article-title":"Streptococcal pharyngitis in children: to treat or not to treat?","volume":"173","author":"Van Brusselen","year":"2014","journal-title":"Eur J Pediatr"},{"issue":"8","key":"10.1016\/j.vaccine.2018.10.001_b0295","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1473-3099(05)70190-0","article-title":"Invasive group A streptococcal disease: should close contacts routinely receive antibiotic prophylaxis?","volume":"5","author":"Smith","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.001_b0300","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2017.17687","article-title":"Enhancing recovery from sepsis: A review","volume":"319","author":"Prescott","year":"2018","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.vaccine.2018.10.001_b0305","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/2047487316640656","article-title":"Infections in early life and premature acute coronary syndrome: a case-control study","volume":"23","author":"Qanitha","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.001_b0310","first-page":"1394","article-title":"Resource utilization and cost of rheumatic fever","volume":"28","author":"Terreri","year":"2001","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.10.001_b0315","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.acvd.2015.12.004","article-title":"The VALVAFRIC study: a registry of rheumatic heart disease in Western and Central Africa","volume":"109","author":"Kingu\u00e9","year":"2016","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.vaccine.2018.10.001_b0320","series-title":"World health statistics 2016: monitoring health for the SDGs sustainable development goals","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.vaccine.2018.10.001_b0325","first-page":"1","article-title":"Group a streptococcal diseases and their global burden","volume":"368","author":"Ralph","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.001_b0330","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1440-1754.2002.00772.x","article-title":"Systematic review of rheumatic heart disease prevalence in children in developing countries: the role of environmental factors","volume":"38","author":"Steer","year":"2002","journal-title":"J Paediatr Child Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:15:50Z","timestamp":1775247350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18313525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":66,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0264410X18313525"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An economic case for a vaccine to prevent group A streptococcus skin infections","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}